New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
14:02 EDTVIVOMeridian granted special 510(k) clearance for TRU FLU in H7N9
Meridian Bioscience announced that the company’s TRU FLU assay received FDA clearance for an analytical sensitivity claim for the novel avian Influenza H7N9 strain, A/Anhui/1/2013. TRU FLU is a rapid immunoassay that detects influenza A and influenza B viruses in 15 minutes in human respiratory specimens. The novel avian Influenza A strain H7N9 was first reported in China last March. Since then, there have been 147 confirmed human cases of avian influenza A H7N9, with 47 deaths reported in China, the company said.
News For VIVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2015
08:02 EDTVIVOMeridian Bioscience reaffirms FY15 EPS view 85c-91c, consensus 86c
Subscribe for More Information
08:02 EDTVIVOMeridian Bioscience reports Q3 EPS 22c, consensus 22c
Reports Q3 revenue $48.2M, consensus $48.6M.
July 20, 2015
09:26 EDTVIVOMeridican says illumigene receives FDA clearance
Meridian Bioscience announced that it has received FDA clearance for two new molecular assays for the detection of Herpes Simplex Virus Type 1 and Type 2, to be run on its illumigene molecular platform. The illumigene HSV 1&2 assays, launched earlier this year in Europe, are now available immediately in the U.S.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use